European medical device company ViCentra has appointed Reman McDonagh, PhD, as its new Vice President of Global Marketing, marking a key move as the company scales commercialization for its Kaleido insulin patch pump system. McDonagh’s hiring comes at a pivotal stage for ViCentra, as it strengthens its European presence and prepares for the next-generation Kaleido system launch in both the EU and the U.S.

The move coincides with ViCentra’s recent $98 million Series D financing extension, providing the financial backing to support ambitious growth plans.

A Proven Diabetes and MedTech Marketing Leader

McDonagh brings over 20 years of experience in diabetes and medical device commercialization, covering the full spectrum from early-stage innovation to large-scale international expansion. Her career includes senior leadership roles at Roche, Medtronic, Cellnovo, and Insulet, with deep experience in brand strategy, go-to-market planning, market development, and high-profile product launches across both mature and emerging markets.

Most recently, she spearheaded Insulet’s Omnipod DASH launch across 12 European countries and contributed to the European strategy for Omnipod 5. Her appointment signals ViCentra’s intent to combine operational rigor with marketing sophistication as it expands its footprint.

“Reman joins ViCentra at a pivotal stage as we transition from strong early traction to disciplined, scalable growth,” said Tom Arnold, CEO of ViCentra. “She brings a rare combination of deep diabetes expertise, end-to-end marketing leadership, and operational rigor, as we strengthen our presence in key European markets and prepare for U.S. market entry.”

Driving Global Marketing Strategy for Kaleido

In her new role, McDonagh will oversee ViCentra’s global marketing strategy, including:

• Strengthening Kaleido’s value proposition

• Accelerating demand generation in priority European markets

• Ensuring cross-functional readiness for upcoming product launches

“Kaleido is a truly differentiated insulin delivery system, and ViCentra has built meaningful momentum through a clear focus on the user experience,” said McDonagh. “I’m excited to join the team as we scale in key markets and prepare for the next generation of Kaleido, bringing greater choice, flexibility, and freedom to more people living with diabetes.”

Bolstering a World-Class Commercial Team

McDonagh’s hiring follows a series of senior commercial leadership additions at ViCentra, reflecting the company’s commitment to building a high-performing, global marketing organization capable of executing its long-term growth strategy. With a PhD in Chemistry and leadership experience managing business units exceeding $400 million in annual revenue, McDonagh brings both technical expertise and commercial acumen.

As ViCentra looks ahead to the EU and U.S. launches of its next-generation Kaleido system, the company is betting that combining innovation with strong marketing leadership will position it as a major player in insulin delivery solutions.

Get in touch with our MarTech Experts.